By exploiting this difference in antigen density, a dual-targeting mechanism optimizes signal integration: the ADGRE2-CAR can decrease ADGRE2 expression by coengaging CLEC12A, achieving more than 80% cytotoxicity in AML xenografts while preserving healthy cells [29]. Here, ADGRE2 is linked to acute myeloid leukemia.